Other Pharmacological interventions

DescriptionStatement levelStatement and Statistics
01 Inositol vs. placebo
01 Y-BOCSs4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between inositol and placebo on reducing obsessive-compulsive symptoms as measured by the Y-BOCS in adults with OCD (N = 1; n = 13; SMD = -0.29; 95% C.I., -1.38 to 0.81)
02 Oxytocin vs. placebo
01 Adverse effectss2yThere is limited evidence suggesting a difference favouring placebo over oxytocin on the likelihood of reporting adverse effects in adults with OCD (N = 1; n = 12; RR = 6.00; 95% C.I., 1.00 to 35.91)
03 Hamilton Depression Scales4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between oxytocin and placebo on reducing depressive symptoms as measured by the Hamilton Depression Scale in adults with OCD (N = 1; n = 12; SMD = 0.38; 95% C.I., -0.77 to 1.52)
04 Self Rating Depression Scales4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between oxytocin and placebo on reducing depressive symptoms as measured by the Self Rating Depression Scale in adults with OCD (N = 1; n = 12; SMD = 0; 95% C.I., -1.13 to 1.13)
05 Hamilton Anxiety Scales4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between oxytocin and placebo on reducing anxiety as measured by the Hamilton Anxiety Scale in adults with OCD (N = 1; n = 12; SMD = 0.22; 95% C.I., -0.92 to 1.36)
06 State Anxiety Inventorys4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between oxytocin and placebo on reducing anxiety as measured by the State Anxiety Inventory in adults with OCD (N = 1; n = 12; SMD = -1.05; 95% C.I., -2.29 to 0.19)
07 General Symptom Indexs4The evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between oxytocin and placebo on reducing general symptoms as measured by the General Symptom Index in adults with OCD (N = 1; n = 12; SMD = 0; 95% C.I., -1.13 to 1.13)

From: Appendix 18, Evidence statements

Cover of Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder: Core Interventions in the Treatment of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder.
NICE Clinical Guidelines, No. 31.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2006.
Copyright © 2006, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.